Expression Pathology Provides Roche its Liquid Tissue®-SRM Protein Biomarker Assay Services in Drug Development
News Jan 12, 2011
Expression Pathology Inc. has announced an agreement with Roche wherein Expression Pathology will provide its Liquid Tissue®-SRM Technology to accelerate identification of cancer molecular markers for developing more effective treatments.
Under the terms of the agreement, Expression Pathology will support Roche oncology drug development programs with multiplexed quantitative assays of cancer signaling pathway proteins and their activation in FFPE tissues by mass spectrometry.
“This new approach to tissue analysis has the potential to dramatically stream-line and improve biomarker identification in FFPE samples during clinical development,” says Dr. Miro Venturi, Senior Biomarker & Experimental Medicine Leader at Roche. “Longer-term, we may envision Expression Pathology’s Liquid Tissue®-SRM platform as becoming a new way of profiling tumors at the molecular level to improve patient stratification and therefore advancing our discovery of personalized medicines.”
“This collaboration with Roche is a key step towards developing valuable clinical assays to improve patient treatment decisions for Roche’s innovative new targeted therapies.” says Casey Eitner, President and CEO of Expression Pathology.
Stable Beta-Amyloid Dimers Identified in Alzheimer’s BrainsNews
A recent study exploited state-of-the-art mass spectrometry to provide the first direct evidence of beta-amyloid dimers in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers. Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.
Protein Target Identified That Could Prevent StrokesNews
Scientists have identified a protein, called GPR68, that senses blood flow and tells small blood vessels called arterioles when to dilate. The researchers believe medications that activate GPR68 could one day be useful to treat medical conditions, including ischemic stroke.READ MORE
Reversing an Unstoppable Cancer Cascade with ProteomicsNews
Mutations in genes that produce RAS proteins turn a normally benign process, essential for cellular growth, into a cancer stimulant that is currently undruggable. Now, cutting-edge protein analysis may help treat cancers caused by these mutations.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018